Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alector, Inc.

Market Cap 164M 142M 130M 122M 230M 15.53B 232M 1.54B 602M 7.6B 617M 604M 26.32B P/E Ratio 2026 *
-1.73x
P/E Ratio 2027 * -2.31x
Enterprise Value -82.82M -71.38M -65.69M -61.63M -116M -7.83B -117M -777M -303M -3.83B -311M -304M -13.26B EV / Sales 2026 *
-12.1x
EV / Sales 2027 * -7.08x
Free-Float
87.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-2.03%
1 week-9.20%
Current month-31.48%
1 month-30.19%
3 months-33.03%
6 months+6.47%
Current year-5.13%
1 week 1.46
Extreme 1.46
1.74
1 month 1.46
Extreme 1.46
2.32
Current year 1.46
Extreme 1.46
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
43.32
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 70 01/05/2013
Director of Finance/CFO 53 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 72 19/03/2024
Chairman 77 13/06/2023
Director/Board Member 72 01/10/2018
Date Insider Type Main position Quantity % Market Cap.
06-03Sell

Controller/Auditor

-3,475 0.0031%
06-02Sell

Chief Financial Officer

-19,360 0.0174%
06-02Sell

Founder

-87,216 0.0786%
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-9.20%-1.99%-80.19% 164M
-0.97%-0.34%+56.37%+107.07% 54.92B
-0.34%+3.51%+45.55%+40.16% 44.31B
-0.57%+4.59%-14.92%-19.62% 22.96B
-1.11%-2.76%-5.20%+381.55% 21.12B
-2.91%+0.27%+13.28%-36.73% 16.31B
-2.42%-2.64%+6.34%-41.43% 15.19B
-0.51%+0.60%+27.69%+179.26% 13.32B
+1.48%+9.81%+19.29% - 12.48B
+0.32%+2.81%+96.37%+213.49% 11.21B
Average -0.83%+1.50%+24.28%+82.62% 21.2B
Weighted average by Cap. -0.71%+2.85%+31.44%+94.27%

Financials

2026 *2027 *
Net sales 6.86M 5.91M 5.44M 5.1M 9.58M 648M 9.68M 64.3M 25.12M 317M 25.73M 25.19M 1.1B 22.88M 19.72M 18.15M 17.03M 31.98M 2.16B 32.3M 215M 83.82M 1.06B 85.87M 84.05M 3.66B
Net income -94.11M -81.11M -74.65M -70.03M -132M -8.89B -133M -883M -345M -4.36B -353M -346M -15.07B -96.62M -83.27M -76.64M -71.9M -135M -9.13B -136M -906M -354M -4.47B -363M -355M -15.47B
Net Debt -247M -213M -196M -184M -345M -23.36B -349M -2.32B -905M -11.44B -927M -908M -39.58B -326M -281M -259M -243M -456M -30.84B -461M -3.06B -1.2B -15.1B -1.22B -1.2B -52.27B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
16/06/26 1.480 $ 0.00% 8,521
15/06/26 1.480 $ -3.27% 629,572
12/06/26 1.530 $ -2.55% 263,831
11/06/26 1.570 $ +3.29% 428,244
10/06/26 1.520 $ -6.75% 429,021
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.480USD
Average target price
3.100USD
Spread / Average Target
+109.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!